Updating results

1412 results

Sort: Relevance | Date

Epilepsies in adults: diagnosis and management update (Please see Epilepsies in children, young people and adults)

In development [GID-NG10110] Expected publication date: 07 April 2021

NICE guideline In development

Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management

In development [GID-NG10091] Expected publication date: 09 December 2020

NICE guideline In development

Perioperative care in adults

In development [GID-NG10072] Expected publication date: TBC

NICE guideline In development

Safeguarding adults in care homes

In development [GID-NG10107] Expected publication date: 21 October 2020

NICE guideline In development

Shared decision making

In development [GID-NG10120] Expected publication date: 14 April 2021

NICE guideline In development

Babies, children and young people's experience of healthcare

In development [GID-NG10119] Expected publication date: 07 April 2021

NICE guideline In development

Neonatal infection (early onset): antibiotics for prevention and treatment

In development [GID-NG10111] Expected publication date: 05 March 2021

NICE guideline In development

Obesity: identification, assessment and management

In development [GID-NG10157] Expected publication date: 23 June 2022

NICE guideline In development

Diabetes update

In development [GID-NG10152] Expected publication date: TBC

NICE guideline In development

Subarachnoid haemorrhage due to ruptured aneurysms

In development [GID-NG10097] Expected publication date: 03 February 2021

NICE guideline In development

Osteoarthritis: care and management (update)

In development [GID-NG10127] Expected publication date: 25 August 2021

NICE guideline In development

Rehabilitation after Traumatic injury

In development [GID-NG10105] Expected publication date: 04 August 2021

NICE guideline In development

Acne Vulgaris: Management

In development [GID-NG10109] Expected publication date: 13 January 2021

NICE guideline In development

Management of gout

In development [GID-NG10151] Expected publication date: 04 April 2022

NICE guideline In development

Depression in adults: treatment and management

In development [GID-CGWAVE0725] Expected publication date: TBC

NICE guideline In development

Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (2019)

In development [GID-NG10087] Expected publication date: 30 March 2020

NICE guideline In development

Joint replacement (primary): hip, knee and shoulder

In development [GID-NG10084] Expected publication date: 25 March 2020

NICE guideline In development

Self-harm in over 8s: management and preventing recurrence

In development [GID-NG10148] Expected publication date: 26 January 2022

NICE guideline In development

Asthma: diagnosis, monitoring and chronic asthma management

In development [GID-NG10143] Expected publication date: 12 February 2020

NICE guideline In development

Abdominal aortic aneurysm: diagnosis and management

In development [GID-CGWAVE0769] Expected publication date: TBC

NICE guideline In development

Acute kidney injury: prevention, detection and management (update)

In development [GID-NG10117] Expected publication date: 18 December 2019

NICE guideline In development

Meningitis (bacterial) and meningococcal septicaemia: recognition, diagnosis and management

In development [GID-NG10149] Expected publication date: 17 February 2022

NICE guideline In development

Chronic kidney disease: assessment and management (update)

In development [GID-NG10118] Expected publication date: 18 March 2021

NICE guideline In development

Guidance on the use of coronary artery stents (TA71)

Evidence-based recommendations on coronary artery stents for treating coronary artery disease (CAD)

Technology appraisal guidance Published October 2003 Last updated July 2008

Guidance on the use of imatinib for chronic myeloid leukaemia (TA70)

Evidence-based recommendations on imatinib (Glivec) for treating chronic myeloid leukaemia (CML)

Technology appraisal guidance Published October 2003 Last updated January 2016

Guidance on the use of liquid-based cytology for cervical screening (TA69)

Evidence-based recommendations on liquid-based cytology (LBC) for cervical screening

Technology appraisal guidance Published October 2003

Human growth hormone (somatropin) in adults with growth hormone deficiency (TA64)

Evidence-based recommendations on human growth hormone (somatropin; Genotropin, Humantrope, Norditropin, Saizen) in adults with growth hormone deficiency

Technology appraisal guidance Published August 2003

Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal) (TA438)

NICE is unable to make a recommendation about the use in the NHS of alectinib for anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer

Technology appraisal guidance Published March 2017

Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal) (TA353)

NICE is unable to make recommendations about the use of bevacizumab for treating relapsed, platinum-resistant epithelial ovarian, fallopian tube or…

Technology appraisal guidance Published August 2015

Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal) (TA362)

NICE is unable to make a recommendation about the use in the NHS of paclitaxel as albumin-bound nanoparticles with carboplatin for untreated..

Technology appraisal guidance Published October 2015

Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy (terminated appraisal) (TA351)

NICE is unable to make recommendations about the use of cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary…

Technology appraisal guidance Published July 2015

Ruxolitinib for treating polycythaemia vera (terminated appraisal) (TA356)

NICE is unable to make a recommendation about the use in the NHS of ruxolitinib for treating polycythaemia vera...

Technology appraisal guidance Published September 2015

Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal) (TA609)

NICE is unable to make a recommendation about the use in the NHS of ramucirumab (Cyramza) for treating unresectable hepatocellular carcinoma after sorafenib

Technology appraisal guidance Published October 2019

Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA611)

Evidence-based recommendations on rucaparib (Rubraca) for relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer that has responded to

Technology appraisal guidance Published November 2019

Pentosan polysulfate sodium for treating bladder pain syndrome (TA610)

Evidence-based recommendations on pentosan polysulfate sodium (Elmiron) for bladder pain syndrome in adults

Technology appraisal guidance Published November 2019

Ibrutinib with rituximab for treating Waldenstrom's macroglobulinaemia (terminated appraisal) (TA608)

NICE is unable to make a recommendation about the use in the NHS of ibrutinib (Imbruvica) with rituximab for treating Waldenstrom’s macroglobulinaemia in adults

Technology appraisal guidance Published October 2019

Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) (TA444)

NICE is unable to make a recommendation about the use in the NHS of afatinib for advanced squamous non-small-cell lung cancer after platinum-based chemotherapy

Technology appraisal guidance Published May 2017

Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours (TA539)

Evidence-based recommendations on lutetium (177Lu) oxodotreotide (Lutathera) for treating unresectable or metastatic neuroendocrine tumours in adults

Technology appraisal guidance Published August 2018

Holoclar for treating limbal stem cell deficiency after eye burns (TA467)

Evidence-based recommendations on Holoclar for treating limbal stem cell deficiency in adults after eye burns

Technology appraisal guidance Published August 2017

Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (TA374)

Evidence-based recommendations on erlotinib (Tarceva) and gefitinib (Iressa) for treating locally advanced or metastatic non-small-cell lung cancer

Technology appraisal guidance Published December 2015

Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer (TA347)

Evidence-based recommendations on nintedanib (Vargatef) for treating locally advanced, metastatic, or locally recurrent non-small-cell lung cancer

Technology appraisal guidance Published July 2015

Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma (TA269)

Evidence-based recommendations on vemurafenib (Zelboraf) for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma

Technology appraisal guidance Published December 2012 Last updated January 2015

Bortezomib and thalidomide for the first‑line treatment of multiple myeloma (TA228)

Evidence-based recommendations on bortezomib (Velcade) and thalidomide (Thalidomide Celgene) for first-line treatment of multiple myeloma

Technology appraisal guidance Published July 2011

Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer (TA395)

Evidence-based recommendations on ceritinib (Zykadia) for advanced anaplastic lymphoma kinase positive non-small-cell lung cancer...

Technology appraisal guidance Published June 2016

Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy (TA598)

Evidence-based recommendations on olaparib (Lynparza) for treating BRCA mutation-positive, advanced ovarian, fallopian tube or primary peritoneal cancer

Technology appraisal guidance Published August 2019

Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (TA569)

Evidence-based recommendations on pertuzumab (Perjeta) for adjuvant treatment (with trastuzumab and chemotherapy) of HER2-positive early stage breast cancer

Technology appraisal guidance Published March 2019

Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA524)

Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating relapsed or refractory CD30-positive Hodgkin lymphoma in adults

Technology appraisal guidance Published June 2018

Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)

Evidence-based recommendations on pertuzumab (Perjeta) for HER2-positive, locally recurrent or metastatic (secondary) breast cancer in adults

Technology appraisal guidance Published March 2018

Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma (TA306)

Evidence-based recommendations on pixantrone (Pixuvri) for treating multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma

Technology appraisal guidance Published February 2014

Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures (TA279)

Evidence-based recommendations on percutaneous vertebroplasty and percutaneous balloon kyphoplasty for osteoporotic vertebral compression fractures

Technology appraisal guidance Published April 2013